Lecanemab Receives Priority Review Status in Japan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/8/2026

1. TTD
2. ABNB
3. NET
4. TEAM
5. DV
6. FROG
7. TWLO
8. CART
9. SPY
10. PUBM

Go back to Lecanemab Receives Priority Review Status in Japan
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 207.94 +1.66 (0.80%)
Previous Close $206.28    52 Week High $333.65 
Open $207.38    52 Week Low $223.02 
Day High $208.31    P/E 26.62 
Day Low $204.16    EPS $7.81 
Volume 877,566